iShares MSCI Europe Quality Dividend ESG UCITS ETF (GB:EQDS) Price & Chart

GB:EQDS ETF Chart & Stats

£639.90

At close: Nov 12 4:00 PM EST

Day’s Range: GBP 638.86 - GBP 642.50
52-Week Range: GBP 539.16 - GBP 642.50
Previous Close: GBP 637.50
Volume: 468.38K
Average Volume (3M): 81.76K
AUM: 982.65M
NAV: 7.64
Expense Ratio: 0.41%
Holdings Count: 74
Beta: 0.84
Inception Date: Jun 12, 2017
Last Dividend Ex-Date: Nov 19, 2026
Dividend Yield: (2.83%)
Shares Outstanding: 115,346,954
Standard Deviation: N/A

ETF Overview

iShares MSCI Europe Quality Dividend ESG UCITS ETF

The iShares MSCI Europe Quality Dividend ESG UCITS ETF, trading under the ticker GB:EQDS, is a sophisticated investment vehicle designed for those seeking exposure to high-quality European companies with strong environmental, social, and governance (ESG) credentials. This ETF is categorized within the Size and Style segment, focusing on the Total Market, making it an ideal choice for investors looking to diversify their portfolios across a broad spectrum of market capitalizations and styles. Uniquely positioned in the Broad-based investment niche, the fund aims to capture the value of European equities that not only offer sustainable dividends but also meet stringent ESG criteria. By integrating quality and ESG factors, the ETF targets companies that have demonstrated robust financial health, consistent earnings growth, and responsible governance practices, making it an attractive option for socially conscious investors who also prioritize financial performance. The iShares MSCI Europe Quality Dividend ESG UCITS ETF offers an engaging blend of sustainability and quality, ensuring that each investment aligns with both ethical values and financial goals. With its comprehensive approach to capturing the essence of the European market, this ETF stands out as a versatile and responsible option for investors aiming to achieve long-term growth and stability.

GB:EQDS ETF News

Novartis reports positive CHMP opinion for Cosentyx in adolescents 12 and older

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Cosentyx for adolescents aged

4h agoNVS NOT

Novartis says long-term Rhapsido data show sustained efficacy

Novartis (NVS) announced 52-week results from the Phase III RemIND program evaluating Rhapsido in chronic inducible urticaria. In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily

1d agoNVS NOT

Midday Fly By: CoreWeave reports beat and raise, OpenAI revenue jumps 50% in Q3

The major averages were higher near noon, led by a big rebound in the Nasdaq as a better-than-expected quarterly report from CoreWeave helped ease concerns around the sustainability of AI

2d agoC DB

CMA says McCormick’s tie up with Unilever’s foods unit could harm competition

Britain’s competition watchdog, the Competition and Markets Authority, has warned that McCormick’s (MKC) proposed merger with Unilever’s (UL) foods business could substantially lessen competition in the U.K. market. The CMA

2d agoUL MKC

Unilever upgraded to Buy from Hold at Deutsche Bank

Deutsche Bank upgraded Unilever (UL) to Buy from Hold with a price target of 5,350 GBp, up from 5,300 GBp. At a time of structural headwinds in the staples sector,

2d agoUL UNV

Novartis presents long-term results from ongoing NEPTUNUS extension study

Novartis (NVS) presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjogren’s disease at the American College of Rheumatology Convergence 2026. The data showed that the reduction

3d agoNVS NOT

0M6S Earnings this Week: How Will it Perform?

Allianz SE (UK) (0M6S) is scheduled to report 3rd quarter earnings on 11/12/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Allianz SE (UK) to post earnings

3d agoALV 0M6S

FDA warns of NAION vision loss risk with GLP-1 RA drugs

The Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy associated with use of glucagon-like peptide-1 receptor

4d agoLLY NVS

Iberdrola upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Robert Pulleyn upgraded Iberdrola (IBDRY) to Overweight from Equal Weight with a EUR 26 price target Published first on TheFly – the ultimate source for real-time, market-moving

4d agoIBE IBDRY

SAP upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded SAP (SAP) to Overweight from Neutral with a price target of EUR 275, up from EUR 175, implying 30% upside. The firm says AI moving from pilot to

4d agoSAP SAPA

Weekend Fly By: Top five stock stories

Catch up on the weekend’s top five stories with this list compiled by The Fly: Nvidia (NVDA) said in a statement that its board is “initiating an independent investigation in

4d agoANT NVS

Novartis to discontinue development of pelacarsen, Bloomberg says

Novartis (NVS) is discontinuing the development of pelacarsen, a drug that was meant to treat atherosclerotic cardiovascular disease, Fabienne Kinzelmann and Robert Langreth of Bloomberg reports. The move comes after

5d agoNVS NOT

Novartis price target raised to CHF 150 from CHF 135 at Citi

Citi raised the firm’s price target on Novartis (NVS) to CHF 150 from CHF 135 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

1w agoNVS NOT

BioArctic says Novartis terminates collaboration agreement

BioArctic AB (BRCTF) announced that Novartis (NVS) has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered into in August 2025 to explore a

1w agoNVS NOT

See More GB:EQDS News

GB:EQDS ETF FAQ

What was GB:EQDS’s price range in the past 12 months?

GB:EQDS’s lowest price in the past 12 months was GBP 539.16 and its highest was GBP 642.50.

What is the AUM of GB:EQDS?

As of Nov 12, 2026, the AUM of GB:EQDS is £982.65M.

Is GB:EQDS overvalued?

Based on Wall Street analyst price targets for GB:EQDS’s holdings, GB:EQDS’s price is currently undervalued.

Does GB:EQDS pay dividends?

Yes. GB:EQDS pays dividends quarterly. Its most recent dividend was £1.78 per share, and its annual dividend yield is 2.83%. See more information on GB:EQDS dividends here.

How many shares outstanding does GB:EQDS have?

GB:EQDS has 115,346,954 shares outstanding.

Top 10 Holdings

The fund's ten largest positions
Name	Weight %
NOVNNovartis	3.86%
ALVAllianz SE (UK)	3.42%
IBEIberdrola SA (UK)	3.14%
SAPSAP SE	2.99%
ULVRUnilever Plc (UK)	2.98%
GIVNGivaudan	2.79%
ZURNZurich Insurance Group	2.70%
RELRELX plc	2.58%
SIKASika AG	2.58%
CSAXA SA (UK)	2.52%
Total	29.56%

See All Holdings

Popular ETFs

Popular ETFs
Company	Price & Change	Follow
SPYSPDR S&P 500 ETF Trust
QQQInvesco QQQ Trust
DIASPDR Dow Jones Industrial Average ETF Trust
IWMiShares Russell 2000 ETF
VOOVanguard S&P 500 ETF